CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey Balloon Aortic Valvuloplasty as a Bridge to Aortic Valve Replacement: A Contemporary Nationwide Perspective Transcatheter Aortic Valve Replacement: Role of Multimodality Imaging in Common and Complex Clinical Scenarios 中国肺动脉高压诊断与治疗指南(2021版) Short Length of Stay After Elective Transfemoral Transcatheter Aortic Valve Replacement Is Not Associated With Increased Early or Late Readmission Risk Change in Kidney Function and 2-Year Mortality After Transcatheter Aortic Valve Replacement Association of Sustained Blood Pressure Control with Multimorbidity Progression Among Older Adults Glycemic Index, Glycemic Load, and Cardiovascular Disease and Mortality von Willebrand Factor and Management of Heart Valve Disease: JACC Review Topic of the Week 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial

Original Research

JOURNAL:CBSMD Article Link

Percutaneous Left Atrial Appendage Occlusion: How Much Do We Know?

CBSMD

Pre-reading

  • Definition of percutaneous left artrail appendage occlusion
  • Indications for LAAO therapy

  • How to define study endpoints, stroke and classifications, transient ischemic attack, cardiovascular mortality, non-cardiovascular mortality, procedural mortality, immediate procedural mortality, systemic embolism, pericardial effusion, bleeding events etc.  




RCTs


Year 2009, "Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial"

confirmed the efficacy of percutaneous closure of the LAA with this device was non-inferior to that of warfarin therapy. Although there was a higher rate of adverse safety events in the intervention group than in the control group, events in the intervention group were mainly a result of periprocedural complications. Closure of the LAA might provide an alternative strategy to chronic warfarin therapy for stroke prophylaxis in patients with non-valvular atrial fibrillation.